Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of the American College of Surgeons"
DOI: 10.1097/xcs.0000000000000714
Abstract: BACKGROUND Young breast cancer (YBC) patients are a unique subpopulation that are often underrepresented in randomized clinical trials. Furthermore, large national cancer databases lack detailed information on recurrence, a meaningful oncologic outcome for young patients.… read more here.
Keywords: her2; breast cancer; recurrence; cohort ... See more keywords
Abstract 625: Cytotoxic T lymphocyte antigen 4 (CTLA-4) expression in ductal carcinoma in situ (DCIS) of the breast
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-625
Abstract: Background: Ductal carcinoma in situ (DCIS) consists of a heterogeneous group that can be subclassified by molecular signatures. High grade DCIS is commonly associated with periductal inflammation, a feature associated with increased risk for microinvasion.… read more here.
Keywords: her2 her2; her2; dcis; ctla expression ... See more keywords
Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital
Sign Up to like & getrecommendations! Published in 2021 at "ecancermedicalscience"
DOI: 10.3332/ecancer.2021.1185
Abstract: Introduction There is extensive evidence associating the response to neoadjuvant chemotherapy (NeoCT) with breast cancer (BC) survival. However, to the author’s knowledge, there is no published data in Chile. The objective of the study is… read more here.
Keywords: chemotherapy; response; breast; her2 her2 ... See more keywords